All In Biotech

NDA 213378 · Alkermes INC

Lybalvi

Olanzapine, Samidorphan L-Malate · Oral · Atypical Antipsychotic

Novel

CDER novel approval, May 28, 2021: To treat schizophrenia and certain aspects of bipolar I disorder

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 28, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

496

150 Phase 3, 32 recruiting

FAERS reports

1,687

418 serious, 18 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Jan 31, 2026.

LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, indicated for the treatment of: Schizophrenia in adults ( 1 ) Bipolar I disorder in adults ( 1 ) Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment

Mechanism: The mechanism of action of olanzapine is unclear; however, its efficacy in the treatment of schizophrenia or bipolar I disorder could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism. The mechanism of action of samidorphan could be mediated through opioid receptor antagonism.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelReview
  • May 28, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelReview
4 products under this application
  • LYBALVI · OLANZAPINE 15MG; SAMIDORPHAN L-MALATE EQ 10MG BASE · TABLET, ORAL · Prescription
  • LYBALVI · OLANZAPINE 5MG; SAMIDORPHAN L-MALATE EQ 10MG BASE · TABLET, ORAL · Prescription
  • LYBALVI · OLANZAPINE 20MG; SAMIDORPHAN L-MALATE EQ 10MG BASE · TABLET, ORAL · Prescription
  • LYBALVI · OLANZAPINE 10MG; SAMIDORPHAN L-MALATE EQ 10MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.

All 496 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use306
  • contraindicated product administered139
  • weight increased91
  • dizziness89
  • drug withdrawal syndrome77
  • insomnia76
  • nausea70
  • weight decreased68
  • vomiting64
  • feeling abnormal61
  • somnolence59
  • fatigue56

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20191
202151
2022360
2023355
2024322
2025338
2026259

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lybalvi (Olanzapine/Samidorphan Malate)

2024 spending

$127M

Beneficiaries

11,665

78,389 claims

Per beneficiary

$10,910

$53.62 per unit

View as table
YearSpending
2020$0
2021$1,692,534
2022$39,162,464
2023$89,971,771
2024$127,260,664

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,214 on PubMed

Sponsor: Alkermes INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.